RecruitingPhase 3NCT06972472
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Sponsor
Eli Lilly and Company
Enrollment
600 participants
Start Date
May 19, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Have body mass index (BMI) ≥25 kilograms per square meter (kg/m2) at screening
- Have type 2 diabetes
- Have hemoglobin A1c (HbA1c) ≥7% and ≤10% at screening
- Have a history of at least one unsuccessful dietary effort to lose body weight
Exclusion Criteria5
- Have type 1 diabetes
- Have an unstable body weight within 90 days prior to screening
- Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening
- Have acute or chronic hepatitis or pancreatitis
- Are taking other medications or alternative remedies to manage weight loss
Interventions
DRUGPlacebo
Administered orally
DRUGOrforglipron
Administered orally
Locations(77)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06972472
Related Trials
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
NCT0724708425 locations
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT0729648446 locations
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
NCT070107571 location
Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes
NCT068364791 location
Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care
NCT071694221 location